Alternative Calibration Strategies for the Clinical Laboratory: Application to Nortriptyline Therapeutic Drug Monitoring

被引:23
|
作者
Olson, Matthew T. [1 ]
Breaud, Autumn [1 ]
Harlan, Robert [1 ]
Emezienna, Nkechinyere [1 ]
Schools, Sabitha [1 ]
Yergey, Alfred L. [2 ]
Clarke, William [1 ]
机构
[1] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA
[2] NICHHD, NIH, Bethesda, MD 20892 USA
关键词
INFECTIOUS-DISEASES-SOCIETY; PERFORMANCE LIQUID-CHROMATOGRAPHY; TANDEM MASS-SPECTROMETRY; PRACTICE GUIDELINES; ANTIDEPRESSANTS; QUANTIFICATION; IMMUNOASSAYS; IONIZATION; STANDARDS; BUSULFAN;
D O I
10.1373/clinchem.2012.194639
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BACKGROUND: The addition of a calibration curve with every run is both time-consuming and expensive for clinical mass spectrometry assays. We present alternative calibration strategies that eliminate the need for a calibration curve except as required by laboratory regulations. METHODS: We measured serum nortriptyline concentrations prospectively in 68 patients on 16 days over a 2-month period using a method employing calibration schemes that relied on the measurement of the response ratio (RR) corrected by the response factor (RF), i.e., a measurement of the RR for an equimolar mixture of the analyte and internal standard. Measurements were taken with contemporaneous RF (cRF) measurements as well as sporadic RF (sRF) measurements. The measurements with these alternative calibration schemes were compared against the clinical results obtained by interpolation on a calibration curve, and those differences were evaluated for analytical and clinical significance. RESULTS: The differences between the values measured by cRF and sRF calibration and interpolation on a calibration curve were not significant (P = 0.088 and P = 0.091, respectively). Both the cRF- and sRF-based calibration results demonstrated a low mean bias against the calibration curve interpolations of 3.69% (95% CI, -15.8% to 23.2%) and 3.11% (95% CI, -16.4% to 22.6%), respectively. When these results were classified as subtherapeutic, therapeutic, or supratherapeutic, there was categorical agreement in 95.6% of the cRF calibration results and 94.1% of the sRF results. CONCLUSIONS: cRF and sRF calibration in a clinically validated liquid chromatography-tandem mass spectrometry assay yields results that are analytically and clinically commensurate to those produced by interpolation with a calibration curve. (C) 2013 American Association for Clinical Chemistry
引用
收藏
页码:920 / 927
页数:8
相关论文
共 50 条
  • [31] THERAPEUTIC DRUG-MONITORING AND TOXICOLOGY - CLINICAL AND LABORATORY INTEGRATION IN THE UNIVERSITY-TEACHING-HOSPITAL
    ROCK, RC
    DECHTIARUK, W
    FRYE, R
    PARRA, K
    CHAN, DW
    PERLSTEIN, MJ
    JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1981, 19 (08): : 818 - 818
  • [32] Therapeutic drug monitoring of antidepressants - clinical aspects
    Laux, G.
    Baumann, P.
    Hiemke, C.
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 2007, (72): : 261 - 267
  • [33] VANCOMYCIN THERAPEUTIC DRUG MONITORING IN CLINICAL PRACTISE
    Suchankova, H.
    Machecova, M.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E107 - E108
  • [34] Therapeutic drug monitoring of aripiprazole in clinical practice
    Wittmann, M.
    Greiner, C. U.
    Haen, E.
    PHARMACOPSYCHIATRY, 2008, 41 (05) : 217 - 217
  • [35] Clinical pharmacology and therapeutic drug monitoring of zonisamide
    Mimaki, T
    THERAPEUTIC DRUG MONITORING, 1998, 20 (06) : 593 - 597
  • [36] THERAPEUTIC DRUG-MONITORING AND CLINICAL PHARMACOKINETICS
    PAXTON, JW
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1981, 11 (05): : 558 - 561
  • [37] Therapeutic Drug Monitoring of Levetiracetam in Clinical Practice
    Salvador-Garrido, P.
    Outeda-Macias, M.
    Martinez-Lopez, L. M.
    Martin-Herranz, I
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 676 - 677
  • [38] Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
    MacDonald, A
    Scarola, J
    Burke, JT
    Zimmerman, JJ
    CLINICAL THERAPEUTICS, 2000, 22 : B101 - B121
  • [39] Therapeutic drug monitoring of amisulpride:: clinical implications
    Müller, MJ
    Sachse, J
    Vernaleken, I
    Gründer, G
    Härtter, S
    Hiemke, C
    PSYCHOPHARMAKOTHERAPIE, 2003, 10 (01): : 23 - 27
  • [40] Therapeutic drug monitoring in a naturalistic clinical setting
    Pfuhlmann, B
    Unterecker, S
    Polok, T
    Burger, R
    Riederer, P
    PHARMACOPSYCHIATRY, 2005, 38 (01) : 59 - 59